Navigation Links
Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
Date:11/1/2007

id-July 2007 that this international Phase 3 trial in Europe and Canada had completed enrollment.

About Hepatitis B

Hepatitis B is a serious disease that affects the liver. It is caused by the hepatitis B virus. Hepatitis B virus is spread through contact with the blood or other body fluids of an infected person. A person can become infected by: contact with a mother's blood and body fluids at the time of birth; contact with blood and body fluids through breaks in the skin such as bites, cuts, or sores; contact with objects that could have blood or body fluids on them such as toothbrushes or razors; having unprotected sex with an infected person; sharing needles when injecting drugs; being stuck with a used needle on the job.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV, a hepatitis B vaccine in Phase 3 partnered with Merck & Co. Inc.; TOLAMBA(TM), a ragweed allergy immunotherapy in Phase 2; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The National Institutes of Health (NIH) partially funds our preclinical work on a vaccine for influenza. Symphony Dynamo, Inc. (SDI) funds our colorectal cancer trials and our preclinical hepatitis C therapeutic program, and Deerfield Management has committed funding for our allergy programs. While Deerfield, NIH and SDI provi
'/>"/>

SOURCE Dynavax Technologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
4. Judgment In Favor Of Merck For Vioxx Drug
5. Merck, ICMR to conduct joint trials on cervical cancer vaccine
6. Merck in the Dock Due To Vioxx
7. Merck Says Januvia Effective In Type 2 Diabetes
8. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
9. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
10. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
11. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... The United States is now mandating that all ... Africa land at one of five airports equipped ... In a statement released Tuesday, Homeland Security ... air passengers from Guinea, Liberia and Sierra Leone ... -- New York City,s Kennedy International Airport, Washington ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open ... American Institutes for Research (AIR) finds that three out of ... insurance, but 42 percent say they are not likely or ... up for coverage. , The AIR survey found wide gaps ... to calculate correctly how much they owe for a routine ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world ... face, it certainly can be difficult to choose the right ... favor by doing it the healthy way? Set aside the ... your body, exercise regularly, and choose foods with the most ... you need to exercise more and eat less. Despite the ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... Haelle HealthDay Reporter , TUESDAY, ... adult men may lead to increased blood pressure, according to ... similar rise in blood pressure for young adult women or ... adult women drank lightly or moderately, their risk of high ... "This finding parallels studies in older adult men and women," ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... new low cost test for acute pancreatitis that gets results ... at The University of Texas at Austin. The sensor, ... is built with a 12-cent LED light, aluminum foil, gelatin, ... The sensor could help prevent damage from acute pancreatitis, ...
... HealthDay Reporter , MONDAY, April 25 (HealthDay News) ... because it does not adequately protect children and pregnant ... new position paper from the American Academy of Pediatrics ... Act (TSCA) in 1976, tens of thousands of new ...
... the ion selectivity of cation-selective channels and transporters. The ... Journal of General Physiology ( www.jgp.org ). ... introduction, a key tool in most recent studies on ... emphasize the fluid-like features of the selectivity filter and ...
... April 25, 2011 Cancer has a mighty big bag ... defense mechanisms and proliferate. Among those tricks is one that ... of lymphatic vessels into something of a highway to metastasis. ... of therapeutics that will put the brakes on such cancer ...
... April 22, 2011 - Sanofi Pasteur, the vaccines division ... announced today that the U.S. Food and Drug Administration ... its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups A, C, ... include a two-dose schedule for infants and children 9 ...
... infections in newborns can lead to serious complications ... pathogens responsible for neonatal infections have changed over ... to at-risk mothers has reduced the incidence of ... A new nationwide, multi-site study aimed at ...
Cached Medicine News:Health News:Self-powered, blood-activated sensor detects pancreatitis quickly and cheaply 2Health News:Pediatricians Urge Better Protection From Chemicals 2Health News:Pediatricians Urge Better Protection From Chemicals 3Health News:Laying bare the not-so-sweet tale of a sugar and its role in the spread of cancer 2Health News:Laying bare the not-so-sweet tale of a sugar and its role in the spread of cancer 3Health News:Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants 2Health News:Streptococci and E. coli continue to put newborns at risk for sepsis 2
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 ... ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting clinical ... Under the terms of the collaboration, Foundation Medicine ... component of Foundation Medicine,s FoundationOne® assay at the WuXi ...
(Date:10/20/2014)... ENGLEWOOD, Colo. , Oct. 20, 2014 /PRNewswire/ ... Inc. (NYSE MKT: AMPE), today announced that its ... the clinical and research potential for its novel ... oxidation-reduction potential (ORP) in the body in response ... clinical value of ORP as a clinical marker ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... , , , , ... The Heart Failure Society of America,s (HFSA) 13th Annual ... in Boston. This three-day meeting -- a forum for heart failure specialists ... trends in research and new developments in the approach to treating patients ...
... , , , ... AMGN ) today announced the presentation of data highlighting ... reduction among women with postmenopausal osteoporosis. The data were presented at ... Research (ASBMR). , , "These data enhance our ...
Cached Medicine Technology:Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench-To-Bedside Approach 2Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench-To-Bedside Approach 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 5Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 6Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 7Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 8Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 9
... for planned ECCE with peristaltic pump ... irrigation, suction, reflux possible with multi-function ... control all critical functions. You can ... and actual vacuum level indicated by ...
...
To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps. - Also available in Titanium...
The CGAL gonioscopic contact glass was designed by Roussel and Fankhauser for,laser treatments of the chamber angle. It reduces the laser spot by a factor of 1.5 as compared to a Goldmann Glass....
Medicine Products: